Immuneering (IMRX) Cash from Financing Activities (2020 - 2024)
Historic Cash from Financing Activities for Immuneering (IMRX) over the last 5 years, with Q4 2024 value amounting to -$40988.0.
- Immuneering's Cash from Financing Activities fell 62313.98% to -$40988.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $5.3 million, marking a year-over-year decrease of 8135.26%. This contributed to the annual value of $5.3 million for FY2024, which is 8135.26% down from last year.
- Per Immuneering's latest filing, its Cash from Financing Activities stood at -$40988.0 for Q4 2024, which was down 62313.98% from $4.4 million recorded in Q3 2024.
- Immuneering's Cash from Financing Activities' 5-year high stood at $118.5 million during Q3 2021, with a 5-year trough of -$184677.0 in Q4 2022.
- Moreover, its 5-year median value for Cash from Financing Activities was $110447.5 (2022), whereas its average is $13.5 million.
- As far as peak fluctuations go, Immuneering's Cash from Financing Activities plummeted by 255613.78% in 2022, and later skyrocketed by 10129786.21% in 2023.
- Over the past 5 years, Immuneering's Cash from Financing Activities (Quarter) stood at $37.0 million in 2020, then crashed by 99.98% to $7519.0 in 2021, then crashed by 2556.14% to -$184677.0 in 2022, then surged by 104.24% to $7835.0 in 2023, then plummeted by 623.14% to -$40988.0 in 2024.
- Its Cash from Financing Activities stands at -$40988.0 for Q4 2024, versus $4.4 million for Q3 2024 and $979923.0 for Q1 2024.